+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

ADC Contract Manufacturing Market (4th Edition) by Phase of Development, Type of Component Manufacturing, Target Indications, Type of Payload Used, Type of Linker, Type of Antibody Origin, Type of Antibody Isotype and Geography, 2020-2030

  • ID: 5215168
  • Report
  • November 2020
  • Region: Global
  • 426 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BioTechnique
  • Eisai
  • iProgen Biotech
  • Nordic Nanovector
  • Sartorius Stedim Biotech

Overview

Since the success of ADCETRIS® (approved in 2011), antibody drug conjugates (ADCs) are now considered a versatile therapeutic tool and have been accepted into the contemporary portfolio of mainstream healthcare solutions. Over time, clinical researchers have been able to further their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. Some of the recently approved ADC therapeutics include BLENREP® (2020), TRODELVYTM (2020), PadcevTM (2019) and POLIVY® (2019). In addition, there are close to 250 unique ADC product candidates under development. Several big pharma players, including AstraZeneca, GlaxoSmithKline, Pfizer, Roche and Takeda, have also acquired stake in this market. Moreover, the fact that companies involved in the development of ADCs, have received over USD 5 billion in capital investments (since 2011), attests to the therapeutic potential and growing popularity of this novel class of targeted therapeutics.  However, the impending growth of the ADC therapeutics market highlights the rising importance of establishing advanced manufacturing capacities in order to meet the anticipated demand. Not all stakeholders in the industry possess end to end capabilities/infrastructure to support the design, development and manufacturing of these complex and highly potent pharmacological entities.

Owing to the fact that ADCs are highly potent, cytotoxic molecules, the manufacturing of such conjugated entities requires elaborate technical capabilities, along with manufacturing acumen related to both biologics and highly potent chemical substances. Specifically, the development of an antibody requires experience in protein engineering, cell line development, bioprocess development and related scale-up techniques. The production of the cytotoxic payloads, which are used in ADCs, requires contained manufacturing facilities, special equipment, and expertise in advanced chemical synthesis and purification techniques. In addition, the process is incomplete without state-of-art linker technologies, which are required for the final bioconjugation step, wherein the antibody component is attached to the cytotoxic payload. Given the aforementioned requirements, industry stakeholders generally do not (entirely) manufacture ADCs in-house. Presently, it is estimated that, 70-80% of ADC manufacturing operations are outsourced. This trend is likely to persist in the coming years, as well. In fact, even some of the leading players in this domain claim to be dependent on contract manufacturers for the supply of one or more components of their respective ADC products/product candidates. All these factors contribute towards increasing the complexity of ADC supply chain. However, as per the recent industry trends, the number of collaborations, strategic alliances and acquisitions have enabled the companies to offer integrated supply chain solutions. Given the anticipated growth in demand for ADCs, the contract manufacturing market in this domain is anticipated to witness substantial growth in the coming years.

Scope of the Report

The “ADC Contract Manufacturing Market (4th Edition) by Phase of Development (Commercial, Phase III, Phase II and Phase I), Type of Component Manufacturing (Antibody Manufacturing, HPAPI/Cytotoxic Payload and Linker Manufacturing, Conjugation and Fill/Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload Used (Maytansinoid, Auristatin, Pseudomonas Exotoxin, PBD and Others), Type of Linker Used (SMCC, VC, Hydrazone Linker, Peptide Linker, SPDB, and Others), Type of Antibody Origin (Humainzed, Human, Murine and Chimeric), Type of Antibody Isotype (IgG1, IgG2 and IgG4) and Geography (North America (the US, Canada, Mexico and Rest of North America), Europe (the UK, Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and Rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and Rest of Latin America) and Rest of the World), 2020-2030” report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain.

In addition to other elements, the study includes:

  • An overview of the current market with respect to the players involved in the contract manufacturing of ADCs. It features information on company size, year of establishment, types of services offered (antibody manufacturing/HPAPI or cytotoxic payload manufacturing/linker manufacturing/conjugation/fill-finish), location of headquarters, location of manufacturing facilities, scale of operations (preclinical, clinical and commercial), and additional development services (proof-of-concept studies/process development and scale-up/analytical development). In addition, the chapter includes details on the antibody contract manufacturers and HPAPI/cytotoxic payload contract manufacturers.    
  • Elaborate profiles of contract manufacturers that offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
  • A competitiveness analysis of contract manufacturers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (company size and its experience in this field), service strength (number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities), manufacturing strength (scale of operation and number of ADC manufacturing facilities) and company size (small-sized, mid-sized and large).
  • A detailed analysis of the expansions undertaken (since 2012) by various service providers for augmenting their respective ADC service portfolios, based on a number of parameters, including year of expansion, type of expansion (capacity expansion and new facility), type of service offered (manufacturing services, analytical/development services and fill/finish), geographical location of facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).
  • An analysis of the recent partnerships (since 2012) focused on manufacturing of ADCs, based on various parameters, such as year of agreement, type of agreement (manufacturing agreement, research agreement, product development, licensing agreement, service alliance, acquisition and others), key players and the geographical distribution of this activity.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.
  • A detailed discussion on various steps of the manufacturing process, namely antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill/finish, of an ADC and the cost requirements across each of the aforementioned stages.
  • An estimate of the overall ADC manufacturing/bioconjugation capacity (in grams/batch) of contract manufacturers based on information provided on their respective websites (wherever available) and additional data collated via secondary and primary research. The analysis highlights the distribution of global capacity by company size (small-sized, mid-sized and large), geographical location of headquarters, geographical location of ADC manufacturing facilities and key players (in terms of highest bioconjugation capacity).
  • An overview of the ADCs that are already approved and those that are under development (clinical and preclinical), featuring information related to their current phase of development (marketed, clinical and preclinical/discovery stage) of lead candidates, target indication(s), target antigen, antibody origin, antibody isotype, type of payload/warhead, type of linker and key players (in terms of number of preclinical molecules).
  • A review of the evolution of ADC conjugation technologies, highlighting the various types pf approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.
  • A comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved/under development). It provides details related to the different types of antibody isotopes, payloads and linkers investigated/being investigated across various geographies, based on the number of trials registered, trial phase, trial status, target indication, type of sponsor/collaborator, number of patients enrolled and duration of the trials.
  • An informed estimate of the annual demand for ADC products (in grams), taking into account commercial, as well as clinical scale requirements, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC capacity, number of registered clinical trials and demand for ADC’s in that particular geographical region.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.
  • An insightful discussion on the impact of COVID-19 pandemic on the ADC contract manufacturing market. In addition, it features various strategies that different companies have adopted/may adopt in order to mitigate the challenges affiliated to the current global crisis.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] phase of development (commercial, phase III, phase II and phase I), [B] type of component manufacturing (antibody manufacturing, HPAPI/cytotoxic payload and linker manufacturing, conjugation and fill/finish), [C] target indications (solid tumors, hematological malignancies and others), [D] type of payload used (maytansinoid, auristatin, pseudomonas exotoxin, PBD and others), [E] type of linker used (SMCC, VC, hydrazone linker, peptide linker, SPDB, and others), [F] type of antibody origin (humainzed, human, murine and chimeric), [G] type of antibody isotype (IgG1, IgG2 and IgG4) and [H] geography (North America (US, Canada, Mexico and rest of North America), Europe (UK, Germany, France, Spain, Italy and rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and rest of Latin America) and rest of the world). To account for the uncertainties associated with the contract manufacturing of ADCs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with key stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)
  • Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
  • John Burt (Chief Executive Officer, Abzena)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
  • Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • David Cunningham (Director Corporate Development, Goodwin Biotechnology)
  • Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Pharma Solutions)
  • Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
  • Anonymous (Director, Business Development, Leading CMO)
  • Anonymous (Chief Executive Officer, Leading CMO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading ADC contract manufacturers, across the world?
  • In which regions are majority of the ADC manufacturing facilities located?
  • What percentage of ADC manufacturing operations are outsourced?
  • What are the key regions targeted by contract manufacturers for expansions or new facility set-up?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What factors are likely to decide if ADC manufacturing should be done in-house or outsourced?
  • What is the overall cost distribution across various steps of ADC manufacturing process?
  • What is overall ADC manufacturing/bioconjugation capacity (in grams/batch) of contract manufacturers?
  • How many ADCs are under development and approved?
  • Which geographies are most active in conducting ADC clinical trials?
  • What is the current, global demand for ADC products?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • BioTechnique
  • Eisai
  • iProgen Biotech
  • Nordic Nanovector
  • Sartorius Stedim Biotech

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4 Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Components of Antibody Drug Conjugates (ADCs)
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker
3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Need for Outsourcing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
3.5. Selecting a CMO Partner

4. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturing Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Service(s) Offered
4.2.4. Analysis by Other ADC Services Offered
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Location of Headquarters
4.2.7. Analysis by Location of Manufacturing Facility
4.3. List of Antibody Contract Manufacturing Service Providers
4.4. List of HPAPI / Cytotoxic Drug Contract Manufacturing Service Providers

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview and Financial Information
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Developments
5.2.5. Future Outlook
5.3. ADC Biotechnology
5.3.1. Company Overview and Financial Information
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Developments
5.3.5. Future Outlook
5.4. Ajinomoto Bio-Pharma Services
5.4.1. Company Overview and Financial Information
5.4.2. ADC Offerings
5.4.3. Manufacturing Facilities
5.4.4. Recent Developments
5.4.5. Future Outlook
5.5. BOC Sciences
5.5.1. Company Overview and Financial Information
5.5.2. ADC Offerings
5.5.3. Manufacturing Facilities
5.5.4. Recent Developments
5.5.5. Future Outlook
5.6. BSP Pharmaceuticals
5.6.1. Company Overview
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.5. Future Outlook
5.7. CARBOGEN AMCIS
5.7.1. Company Overview
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Developments
5.7.5. Future Outlook
5.8. Cerbios-Pharma
5.8.1. Company Overview
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Developments
5.8.5. Future Outlook
5.9. Creative Biolabs
5.9.1. Company Overview
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Developments
5.9.5. Future Outlook
5.10. Goodwin Biotechnology
5.10.1. Company Overview
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Developments
5.10.5. Future Outlook
5.11. Lonza
5.11.1. Company Overview and Financial Information
5.11.2. ADC Offerings
5.11.3. Manufacturing Facilities
5.11.4. Recent Developments
5.11.5. Future Outlook
5.12. MabPlex
5.12.1. Company Overview
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Developments
5.12.5. Future Outlook
5.13. Millipore Sigma
5.13.1. Company Overview
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Developments
5.13.5. Future Outlook
5.14. Novasep
5.14.1. Company Overview
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Future Outlook
5.15. Pierre Fabre
5.15.1. Company Overview and Financial Information
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Developments
5.15.5. Future Outlook
5.16. Piramal Pharma Solutions
5.16.1. Company Overview and Financial Information
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Developments
5.16.5. Future Outlook
5.17. WuXi Biologics
5.17.1. Company Overview and Financial Information
5.17.2. ADC Offerings
5.17.3. Manufacturing Facilities
5.17.4. Recent Developments
5.17.5. Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. ADC Contract Manufacturing Service Providers
6.3.1. ADC Contract Manufacturing Service Providers based in North America
6.3.2. ADC Contract Manufacturing Service Providers based in Europe
6.3.3. ADC Contract Manufacturing Service Providers based in Asia-Pacific and Rest of the World

7. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: RECENT EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturing Service Providers: Recent Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service(s) Offered
7.2.4. Analysis by Location of Expanded Facility
7.2.5. Analysis by Scale of Operation
7.2.6. Most Active Players: Analysis by Number of Expansions

8. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturing Service Providers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Most Active Players
8.3.4.2. Intercontinental and Intracontinental Agreements

9. MAKE VERSUS BUY DECISION MAKING
9.1. Chapter Overview
9.2. Assumptions and Parameter Definitions
9.2.1. Scenario 1
9.2.2. Scenario 2
9.2.3. Scenario 3
9.2.4. Scenario 4
9.3. Concluding Remarks

10. VALUE CHAIN ANALYSIS
10.1. Chapter Overview
10.2. ADC Development Value Chain
10.3. Cost Distribution Across the Value Chain
10.3.1. Cost Associated with Antibody Manufacturing
10.3.2. Cost Associated with Payload and Linker Manufacturing
10.3.3. Cost Associated with Conjugation
10.3.4. Cost Associated with Fill / Finish

11. ADC MANUFACTURING: CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. ADC Manufacturing: Global Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Headquarters
11.3.3. Analysis by Location of Manufacturing Facilities
11.3.3.1 By Country
11.3.3.2. By Continent
11.3.4. Analysis by Key Players

12. ADC THERAPEUTICS: MARKET OVERVIEW
12.1. Chapter Overview
12.2. ADC Therapeutics: Clinical Pipeline
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Target Indication
12.2.3. Analysis by Target Antigen
12.2.4. Analysis by Antibody Origin
12.2.5. Analysis by Type of Antibody Isotype
12.2.6. Analysis by Payload Type
12.2.7. Analysis by Linker Type
12.3. ADC Therapeutics: Preclinical / Discovery Pipeline
12.3.1. Key Technology Providers: Analysis by Number of ADC Therapeutics

13. NOVEL ADC CONJUGATION TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. First Generation ADC Technologies
13.3. Second Generation ADC Technologies
13.3.1. Cysteine and Selenocysteine Engineering
13.3.2. Unnatural Amino Acid Engineering
13.3.3. Amino-Terminal Serine Engineering
13.4. Third Generation ADC Technologies
13.4.1. Enzyme-Assisted Ligation Approaches
13.4.2. Glycan Remodeling Approaches
13.4.3. Ligation at Fab Nucleotide-Binding Site
13.4.4. Cysteine Re-bridging
13.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
13.5. Evolutionary Analysis

14. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. ADC Therapeutics: Overall Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Trial Phase
14.3.3. Analysis by Trial Status
14.3.4. Analysis by Type of Sponsor / Collaborator
14.3.5. Analysis by Type of Cancer
14.3.6. Most Active Players: Analysis by Number of Clinical Trials
14.3.7. Geographical Analysis by Number of Clinical Trials
14.3.8. Geographical Analysis by Enrolled Patient Population
14.4. ADC Therapeutics: Geographical Clinical Trial Analysis by Antibody Isotope
14.4.1. IgG1 based Molecules
14.4.1.1. Geographical Analysis by Trial Phase
14.4.1.2. Geographical Analysis by Trial Status
14.4.1.3. Geographical Analysis by Enrolled Patient Population
14.4.1.4. Analysis by Duration of Clinical Trials
14.4.2. IgG2 based Molecules
14.4.2.1. Geographical Analysis by Trial Phase
14.4.2.2. Geographical Analysis by Trial Status
14.4.2.3. Geographical Analysis by Enrolled Patient Population
14.4.2.4. Analysis by Duration of Clinical Trials
14.4.3. IgG4 based Molecules
14.4.3.1. Geographical Analysis by Trial Phase
14.4.3.2. Geographical Analysis by Trial Status
14.4.3.3. Geographical Analysis by Enrolled Patient Population
14.4.3.4. Analysis by Duration of Clinical Trials
14.5. ADC Therapeutics: Geographical Clinical Trial Analysis by Payload Type
14.5.1. Auristatin based Molecules
14.5.1.1. Geographical Analysis by Trial Phase
14.5.1.2. Geographical Analysis by Trial Status
14.5.1.3. Geographical Analysis by Enrolled Patient Population
14.5.1.4. Analysis by Duration of Clinical Trials
14.5.2. Maytansinoid based Molecules
14.5.2.1. Geographical Analysis by Trial Phase
14.5.2.2. Geographical Analysis by Trial Status
14.5.2.3. Geographical Analysis by Enrolled Patient Population
14.5.2.4. Analysis by Duration of Clinical Trials
14.5.3. Calicheamicin based Molecules
14.5.3.1. Geographical Analysis by Trial Phase
14.5.3.2. Geographical Analysis by Trial Status
14.5.3.3. Geographical Analysis by Enrolled Patient Population
14.5.3.4. Analysis by Duration of Clinical Trials
14.5.4. PBD based Molecules
14.5.4.1. Geographical Analysis by Trial Phase
14.5.4.2. Geographical Analysis by Trial Status
14.5.4.3. Geographical Analysis by Enrolled Patient Population
14.5.4.4. Analysis by Duration of Clinical Trials
14.5.5. Camptothecin based Molecules
14.5.5.1. Geographical Analysis by Trial Phase
14.5.5.2. Geographical Analysis by Trial Status
14.5.5.3. Geographical Analysis by Enrolled Patient Population
14.5.5.4. Analysis by Duration of Clinical Trials
14.5.6. Pyranoindolizinoquinoline based Molecules
14.5.6.1. Geographical Analysis by Trial Phase
14.5.6.2. Geographical Analysis by Trial Status
14.5.6.3. Geographical Analysis by Enrolled Patient Population
14.5.6.4. Analysis by Duration of Clinical Trials
14.5.7. Other Payload based Molecules
14.5.7.1. Geographical Analysis by Trial Phase
14.5.7.2. Geographical Analysis by Trial Status
14.5.7.3. Geographical Analysis by Enrolled Patient Population
14.5.7.4. Analysis by Duration of Clinical Trials
14.6. ADC Therapeutics: Geographical Clinical Trial Analysis by Linker Type
14.6.1. VC based Molecules
14.6.1.1. Geographical Analysis by Trial Phase
14.6.1.2. Geographical Analysis by Trial Status
14.6.1.3. Geographical Analysis by Enrolled Patient Population
14.6.1.4. Analysis by Duration of Clinical Trials
14.6.2. Hydrazone Linker based Molecules
14.6.2.1. Geographical Analysis by Trial Phase
14.6.2.2. Geographical Analysis by Trial Status
14.6.2.3. Geographical Analysis by Enrolled Patient Population
14.6.2.4. Analysis by Duration of Clinical Trials
14.6.3. SMCC based Molecules
14.6.3.1. Geographical Analysis by Trial Phase
14.6.3.2. Geographical Analysis by Trial Status
14.6.3.3. Geographical Analysis by Enrolled Patient Population
14.6.3.4. Analysis by Duration of Clinical Trials
14.6.4. Peptide Linker based Molecules
14.6.4.1. Geographical Analysis by Trial Phase
14.6.4.2. Geographical Analysis by Trial Status
14.6.4.3. Geographical Analysis by Enrolled Patient Population
14.6.4.4. Analysis by Duration of Clinical Trials
14.6.5. SPDB based Molecules
14.6.5.1. Geographical Analysis by Trial Phase
14.6.5.2. Geographical Analysis by Trial Status
14.6.5.3. Geographical Analysis by Enrolled Patient Population
14.6.5.4. Analysis by Duration of Clinical Trials
14.6.6. MC based Molecules
14.6.6.1. Geographical Analysis by Trial Phase
14.6.6.2. Geographical Analysis by Trial Status
14.6.6.3. Geographical Analysis by Enrolled Patient Population
14.6.6.4. Analysis by Duration of Clinical Trials
14.6.7. Others Type Linker based Molecules
14.6.7.1. Geographical Analysis by Trial Phase
14.6.7.2. Geographical Analysis by Trial Status
14.6.7.3. Geographical Analysis by Enrolled Patient Population
14.6.7.4. Analysis by Duration of Clinical Trials

15. ADC THERAPEUTICS: DEMAND ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. ADC Therapeutics: Overall Annual Demand
15.3.1. ADC Therapeutics: Annual Commercial Demand
15.3.1.1. Analysis by Type of Cancer
15.3.1.2. Analysis by Antibody Origin
15.3.1.3. Analysis by Type of Antibody Isotype
15.3.1.4. Analysis by Payload Type
15.3.1.5. Analysis by Linker Type
15.3.2. ADC Therapeutics: Annual Clinical Demand
15.3.2.1. Analysis by Phase of Development
15.3.2.2. Analysis by Type of Cancer
15.3.2.3. Analysis by Antibody Origin
15.3.2.4. Analysis by Type of Antibody Isotype
15.3.2.5. Analysis by Payload Type
15.3.2.6. Analysis by Linker Type
15.3.2.7. Analysis by Key Geographical Regions
15.4. ADC Therapeutics: Demand and Supply Analysis

16. REGIONAL CAPABILITY ASSESSMENT ANALYSIS
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Regional Capability Assessment in North America
16.4. Regional Capability Assessment in Europe
16.5. Regional Capability Assessment in Asia-Pacific Region

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology
17.3. Overall ADC Therapeutics Market, 2020-2030
17.4. Input Data and Key Assumptions
17.5. Overall ADC Contract Manufacturing Market, 2020-2030
17.5.1. ADC Contract Manufacturing Market, 2020-2030: Distribution by Type of Component Manufacturing
17.5.2. ADC Contract Manufacturing Market, 2020-2030: Distribution by Phase of Development
17.6. ADC Contract Manufacturing Market for Commercial Products, 2020-2030
17.6.1. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Component Manufacturing
17.6.2. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Cancer
17.6.3. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Origin
17.6.4. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Antibody Isotype
17.6.5. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Payload Type
17.6.6. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Linker Type
17.6.7. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Key Geographical Regions
17.6.7.1. ADC Contract Manufacturing Market for Commercial Products in North America, 2020-2030
17.6.7.2. ADC Contract Manufacturing Market for Commercial Products in EU5, 2020-2030
17.6.7.2. ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2020-2030
17.7. ADC Contract Manufacturing Market for Clinical Products, 2020-2030
17.7.1. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Component Manufacturing
17.7.2. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Cancer
17.7.3. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Origin
17.7.4. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Antibody Isotype
17.7.5. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Payload Type
17.7.6. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Linker Type
17.7.7. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Key Geographical Regions
17.7.7.1. ADC Contract Manufacturing Market for Clinical Products in North America, 2020-2030
17.7.7.2. ADC Contract Manufacturing Market for Clinical Products in Europe, 2020-2030
17.7.7.3. ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2020-2030
17.7.7.4. ADC Contract Manufacturing Market for Clinical Products in MENA, 2020-2030
17.7.7.5. ADC Contract Manufacturing Market for Clinical Products in Latin America, 2020-2030
17.7.7.6. ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2020-2030

18. SWOT ANALYSIS
18.1. Chapter Overview
18.1.1. Strengths
18.1.2. Weaknesses
18.1.3. Opportunities
18.1.4. Threats

19. IMPACT OF COVID-19 PANDEMIC ON THE ADC CONTRACT MANUFACTURING MARKET
19.1 Chapter Overview
19.2. Current Opinions and Recuperative Initiatives of Key Players
19.2.1. ADC Biotechnology
19.2.2. Ajinomoto Bio-Pharma Services
19.2.3. CARBOGEN AMCIS
19.2.4. Goodwin Biotechnology
19.2.5. Lonza
19.2.6. Millipore Sigma
19.2.7. Novasep
19.2.8. Pierre Fabre
19.2.9. Piramal Pharma Solutions
19.2.10. Wuxi Biologics
19.3. Impact on ADC Contract Manufacturing Market
19.4. Recuperative Strategies for Contract Service Providers
19.4.1. Strategies for Implementation in the Short / Mid Term
19.4.2. Strategies for Implementation in the Long Term

20. CONCLUDING REMARKS
20.1. Chapter Overview

21. INTERVIEW TRANSCRIPTS
21.1. Chapter Overview
21.2. BSP Pharmaceuticals
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager
21.3. Oxford BioTherapeutics
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Christian Rohlff, Chief Executive Officer & Founder
21.4. Abzena
21.4.1. Company Snapshot
21.4.2. Interview Transcript: John Burt, Chief Executive Officer
21.5. Syndivia
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Sasha Koniev, Chief Executive Officer & Co-Founder
21.6. Cerbios-Pharma
21.6.1. Company Snapshot
21.6.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
21.7. NBE-Therapeutics
21.7.1. Company Snapshot
21.7.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer
21.8. Eisai
21.8.1. Company Snapshot
21.8.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer
21.9. Synaffix
21.9.1. Company Snapshot
21.9.2. Interview Transcript: Anthony DeBoer, Director, Business Development
21.10. Pierre Fabre
21.10.1. Company Snapshot
21.10.2. Interview Transcript: Christian Bailly, Director of CDMO
21.11. Goodwin Biotechnology
21.11.1. Company Snapshot
21.11.2. Interview Transcript: David Cunningham, Director Corporate Development
21.12. Catalent Pharma Solutions
21.12.1. Company Snapshot
21.12.2. Interview Transcript: Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager
21.13. Lonza
21.13.1. Company Snapshot
21.13.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development
21.14. Piramal Pharma Solutions
21.14.1. Company Snapshot
21.14.2. Interview Transcript: Mark Wright, Site Head
21.15. Ajinomoto Bio-Pharma Services
21.15.1. Company Snapshot
21.15.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager
21.16. Anonymous, Director, Business Development, Leading CMO
21.17. Anonymous, Chief Executive Officer, Leading CMO

22. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
  • 3P Biopharmaceuticals
  • AB SCiex
  • AbbVie
  • AbbVie Contract Manufacturing
  • AbGenomics International
  • Advanced BioScience Laboratories (ABL)
  • ABL Bio
  • Abzena
  • ACES Pharma
  • Adagene
  • ADC Biotechnology
  • ADC Therapeutics
  • Aenova
  • Affinity Life Sciences
  • AGC Biologics
  • Agno Pharma
  • Ajinomoto Bio-Pharma Services
  • ALB Technology
  • Albany Molecular Research (AMRI)
  • Alcami
  • Aldevron
  • Algeta
  • Alkermes Contract Pharma Services
  • Allele Biotechnology & Pharmaceuticals
  • Allergan
  • Almac
  • Alphora Research
  • Alteogen
  • Alvotech
  • Ambrx
  • Amgen
  • AMPAC Fine Chemicals
  • Angiex
  • Antibodies Incorporated
  • Antibody Production Services (division of Life Science Group)
  • Aptuit
  • Arabio
  • Arch Pharmalabs
  • Ardena
  • Asana BioSciences
  • Ash Stevens
  • Aspen Oss
  • Aspyrian Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Asymchem Laboratories
  • AutekBio
  • Avacta
  • Avanthera
  • Avid Bioservices
  • Axcellerate Pharma
  • Batavia Biosciences
  • Baxter BioPharma Solutions
  • Bayer
  • BeiGene
  • Beth Israel Deaconess Medical Center
  • BIBITEC
  • Binex
  • BioAtla
  • BioInvent International
  • Biomay
  • BioMed Valley Discoveries
  • Biosynergy (Europe)
  • Bio-Synthesis
  • BioTechnique
  • Biotecnol
  • Biotest
  • Bio-Thera Solutions
  • BioVectra
  • Biovian
  • BioVolutions
  • BioWa
  • BlinkBio
  • Bliss Biopharamceutical
  • BOC Sciences
  • Boehringer Ingelheim BioXcellence
  • Bolt Biotherapeutics
  • Bristol-Myers Squibb
  • Bryllan
  • BSP Pharmaceuticals
  • Burrard Pharmaceuticals
  • Cambrex
  • Capsugel
  • CARBOGEN AMCIS
  • Catalent Pharma Solutions
  • Celgene
  • Cell Culture Company
  • Cellerant Therapeutics
  • CellMosaic
  • Celltrion
  • Celon Labs
  • Celonic
  • Centrose
  • Cerbios-Pharma
  • ChemCon
  • ChemPartner
  • ChemSun Pharmaceutical
  • Chugai Pharmaceuticals
  • CinnaGen
  • CMAB Biopharma
  • CMC Biologics
  • Cobra Biologics
  • Coldstream Laboratories
  • Concortis Biosystems
  • Consort Medical
  • CordenPharma
  • Creative Biolabs
  • CSPC Pharmaceutical
  • CureMeta
  • CytomX Therapeutics
  • Cytopharma
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dalton Pharma Services
  • Debiopharm
  • Diatec Monoclonals
  • DM Bio
  • Dorizoe Lifesciences
  • Dottikon Exclusive Synthesis
  • Dr. Reddy's Custom Pharmaceutical Services
  • EirGen Pharma
  • EirGenix
  • Eisai
  • EMD Serono
  • Emergent BioSolutions
  • Esperance Pharmaceuticals
  • Etinpro
  • EuBiologics
  • Eurofins CDMO
  • Eurogentec
  • Evonik
  • Excella
  • Exelixis
  • Farmabios
  • Farmhispania Group
  • Fermion
  • FineTech Pharmaceuticals
  • Flamma
  • Formation Biologics
  • Formex
  • Formosa Laboratories
  • For‐Robin
  • Fortis Therapeutics
  • Fosun Pharma
  • Fresenius Kabi
  • Fudan-Zhangjiang Bio-Pharmaceutical
  • FUJIFILM Diosynth Biotechnologies
  • GamaMabs Pharma
  • GEA Pharma Systems
  • Genentech
  • Genmab
  • GENTEC Pharmaceutical Group
  • German Cancer Research Center (DKFZ)
  • GlaxoSmithKline
  • Glenmark
  • Goodwin Biotechnology
  • GP Pharm
  • GSK
  • GT Biopharma
  • GTP Technology
  • HALIX
  • Hangzhou DAC Biotech
  • Heidelberg Pharma
  • Helsinn Advanced Synthesis
  • Heraeus
  • Hovione
  • iBIOSOURCE
  • Iconic Therapeutics
  • ICROM
  • Idifarma
  • IDT Australia
  • IDT Biologika
  • Igenica Biotherapeutics
  • Iksuda Therapeutics
  • ImmunoBiochem
  • ImmunoGen
  • Immunomedics
  • Indena
  • Innate Pharma
  • Inno Biologics
  • Intas
  • Intellect Neurosciences
  • iProgen Biotech
  • JHL Biotech
  • Jiangsu Hengrui Medicine
  • Johns Hopkins University
  • Johnson Matthey Pharma Services
  • KBI Biopharma
  • Kemwell Biopharma
  • Klus Pharma
  • Kodiak
  • KUBio (a manufacturing unit of GE Healthcare)
  • Kyongbo Pharmaceutical
  • Labochim
  • LakePharma
  • LAMPIRE Biological Laboratories
  • Laureate Biopharmaceutical Services
  • LegoChem Biosciences
  • Leica Biosystems
  • Levena Biopharma
  • LFB Biomanufacturing
  • Light Chain Bioscience
  • LinXis
  • Lonza
  • MAB Discovery
  • Mabion
  • MabPlex
  • MabVax
  • Mab-Venture Biopharma
  • Mac-Chem
  • MacroGenics
  • Magenta Therapeutics
  • Magle Chemoswed
  • Maine Biotechnology Services
  • MassBiologics
  • Max Delbrück Center for Molecular Medicine
  • Mayne Pharma
  • MediaPharma
  • Medichem
  • MedImmune
  • Medix Biochemica
  • Menarini
  • Menarini Biotech
  • Merck
  • Merck Millipore
  • Meridian Life Science
  • Mersana Therapeutics
  • Metrics Contract Services
  • MilliporeSigma
  • Minafin Group
  • Miracogen
  • Mitsubishi Tanabe Pharma
  • Mologic
  • MorphoSys
  • Morphotek
  • MuseChem
  • Mycenax Biotech
  • NanoValent Pharmaceuticals
  • National Cancer Institute
  • National Institutes of Health
  • Navrogen
  • NBE-Therapeutics
  • NerPharma
  • Nerviano Medical Sciences
  • Nitto Avecia Pharma Services
  • NJ Bio
  • Nordic Nanovector
  • Normon
  • Northway Biotechpharma
  • Novasep
  • NovoCodex Biopharmaceuticals
  • OBI Pharma
  • OGD2 Pharma
  • Ology Bioservices
  • Olon
  • Oncolinx
  • Oncomatryx Biopharma
  • Oncotec Pharma
  • Orano Med
  • OsoBio (a subsidiary of AMRI)
  • Oxford BioTherapeutics
  • Particle Sciences
  • Patheon
  • Paul Scherrer Institute
  • PCI Pharma Services
  • Pensatech Pharma
  • Pfanstiehl
  • Pfizer
  • Pfizer CentreOne
  • Pharmaceutics International
  • PharmaMar
  • Pharmascience
  • Pharmedartis
  • Philochem
  • Pierre Fabre
  • Piramal Pharma Solutions
  • PMI BioPharma Solutions
  • Polymun Scientific
  • PrasFarma
  • Praxis Pharmaceutical
  • Premas Biotech
  • ProBioGen
  • Procos
  • ProJect Pharmaceutics
  • ProteoGenix
  • PX'Therapeutics
  • Quality Assistance
  • Quotient Sciences
  • Radimmune Therapeutics
  • Rakuten Medical
  • Recipharm
  • Redwood Bioscience
  • Regeneron Pharmaceuticals
  • Regis Technologies
  • RemeGen
  • Rentschler Biopharma
  • Research Corporation Technologies
  • Richman Chemical
  • Richter-Helm BioLogics
  • Roche
  • SAFC
  • Saltigo
  • Samsung BioLogics
  • Samsung Medical Center
  • Sanofi Active Ingredient Solutions
  • Sanofi
  • Sartorius Stedim Biotech
  • ScinoPharm
  • SDIX
  • Seattle Genetics
  • Servier
  • Shanghai Jiaolian Drug Development
  • Shanghai Pharmaceuticals
  • Shenogen Pharma
  • Siam Bioscience
  • Siamab Therapeutics
  • Siegfried
  • Somatek
  • Sorrento Therapeutics
  • Spirogen
  • STA Pharmaceutical
  • Stason Pharmaceuticals
  • Stemcentrx
  • Sutro Biopharma
  • Symbiosis Pharmaceutical Services
  • Synaffix
  • Syndivia
  • Syngene
  • Synthon
  • Symphogen
  • Takara Bio
  • Takeda Oncology
  • TBD-Biodiscovery
  • Telix Pharmaceuticals
  • Teresi Pharmaceuticals
  • Teva api
  • The Chemistry Research Solution
  • The Hong Kong Institute of Biotechnology
  • The Native Antigen Company
  • Therapure Biopharma
  • Thermo Fisher Scientific
  • Tot Biopharm
  • Toyobo Biologics
  • Transporin
  • TRIANNI
  • TRIO Pharmaceuticals
  • Triphase Accelerator
  • Tsinghua University Innovation Center for Immune Therapy
  • TUBE Pharma
  • University Medical Center Groningen
  • University of California
  • University of California, San Francisco
  • University of Freiburg
  • UPM Pharmaceuticals
  • Uquifa
  • Vaccinex
  • VelosBio
  • Vibalogics
  • Visterra
  • VUAB Pharma
  • Waisman Biomanufacturing
  • Waterstone Pharmaceuticals
  • WHP Engineering
  • WuXi AppTec
  • WuXi Biologics
  • Wyeth-Ayerst Laboratories
  • Xintela
  • Y-Biologics
  • Yale School of Medicine
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Teruisi Pharmaceutical
  • Zymeworks
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll